Hyperkalemia risk and potassium trajectory after finerenone initiation: a real-world cohort study
Clinical and Experimental Nephrology · 2026-10 · 30 (10) · 1433-1440
DOI: 10.1007/s10157-026-02898-7 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical and Experimental Nephrology, online erschienen am 08.06.2026. Verfasst von Nobuhiro Hashimoto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan. bosuhiro2005@yahoo.co.jp. Hauptthemen laut MEDLINE: Hyperkalemia, Potassium, Naphthyridines, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Finerenone improves cardiovascular and kidney outcomes in patients with type 2 diabetes and chronic kidney disease; however, hyperkalemia remains a safety concern in routine practice. We evaluated the incidence of hyperkalemia, factors associated with its occurrence, and temporal patterns of serum potassium after finerenone initiation. METHODS: We conducted a single-center retrospective observational cohort study of patients who initiated finerenone between May 2022 and August 2025. The primary outcome was incident hyperkalemia (serum potassium ≥ 5.5 mEq/L). Candidate variables were selected using least absolute shrinkage and selection operator (LASSO)-penalized Cox regression, and associations were estimated using multivariable Cox proportional hazards models. Potassium trajectories were assessed using mixed-effects models over 12 months (6 months before and after finerenone initiation), with subgroup analyses by kidney function and baseline potassium. RESULTS: Among 289 eligible patients, 280 were included (mean age 68 years; 68% male; mean baseline eGFR of 36.8 mL/min/1.73 m2). Hyperkalemia occurred in 38 patients. Incident hyperkalemia was associated with higher baseline potassium and log-transformed C-reactive protein and with use of diuretics and potassium binders. Mean serum potassium increased by approximately 0.10 mEq/L over six months, with the largest rise in the first 1-2 months. Patients with eGFR < 30 mL/min/1.73 m2 or baseline potassium ≥ 4.5 mEq/L had higher potassium levels throughout follow-up. CONCLUSIONS: Finerenone was generally well tolerated, with modest potassium increases. In our real-world cohort, hyperkalemia occurred in a notable proportion of patients, underscoring the importance of early monitoring, particularly in those with reduced kidney function or elevated baseline potassium.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan. bosuhiro2005@yahoo.co.jp.
- Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.
- Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan.
- Division of Cardiology, Osaka General Medical Center, Osaka, Japan.
Zitieren
APA
Hashimoto, N., Sakaguchi, Y., Naito, M., Makino, S., Takashima, A., Miyakawa, H., Okushima, H., Asai, M., & Hayashi, T. (2026). Hyperkalemia risk and potassium trajectory after finerenone initiation: a real-world cohort study. Clinical and Experimental Nephrology, 30(10), 1433-1440. https://doi.org/10.1007/s10157-026-02898-7
Vancouver
Hashimoto N, Sakaguchi Y, Naito M, Makino S, Takashima A, Miyakawa H, et al. Hyperkalemia risk and potassium trajectory after finerenone initiation: a real-world cohort study. Clinical and Experimental Nephrology. 2026;30(10):1433-1440. doi:10.1007/s10157-026-02898-7
BibTeX
@article{Hashimoto2026,
author = {Hashimoto, Nobuhiro and Sakaguchi, Yusuke and Naito, Miyu and Makino, Syuzo and Takashima, Akito and Miyakawa, Hiromitsu and Okushima, Hiroki and Asai, Mitsutoshi and Hayashi, Terumasa},
title = {Hyperkalemia risk and potassium trajectory after finerenone initiation: a real-world cohort study},
journal = {Clinical and Experimental Nephrology},
year = {2026},
volume = {30},
number = {10},
pages = {1433--1440},
doi = {10.1007/s10157-026-02898-7}
}
EUVIMED